Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI.
Am J Obstet Gynecol. 2023 Oct;229(4):419.e1-419.e10. doi: 10.1016/j.ajog.2023.07.013. Epub 2023 Jul 13.
The impact of gender-affirming testosterone on fertility is poorly understood, with ovarian histopathologic studies showing variable results, some with a detrimental effect on reproductive capacity and uncertain reversibility. Assisted reproductive outcome data are restricted to small case series that lack the ability to inform clinical practice guidelines and limit fertility preservation counseling for transgender and nonbinary individuals.
This study aimed to determine the impact of current testosterone and testosterone washout on in vitro fertilization outcomes in a mouse model for gender-affirming hormone treatment. We hypothesized that current or previous testosterone treatment would not affect in vitro fertilization outcomes.
C57BL/6N female mice (n=120) were assigned to 4 treatment groups: (1) current control, (2) current testosterone, (3) control washout, and (4) testosterone washout. Testosterone implants remained in situ for 6 or 12 weeks, representing the short- and long-term treatment arms, respectively. Current treatment groups underwent ovarian stimulation with implants in place, and washout treatment groups were explanted and had ovarian stimulation after 2 weeks. Oocytes were collected, fertilized, and cultured in vitro, with one arm continuing to the blastocyst stage and the other having transfer of cleavage-stage embryos. Statistical analysis was performed using GraphPad Prism, version 9.0 and R statistical software, version 4.1.2, with statistical significance defined by P<.05.
Current long-term testosterone treatment impaired in vitro fertilization outcomes, with fewer mature oocytes retrieved (13.7±5.1 [standard deviation] vs 28.6±7.8 [standard deviation]; P<.0001) leading to fewer cleavage-stage embryos (12.1±5.1 vs 26.5±8.2; P<.0001) and blastocysts (10.0±3.2 vs 25.0±6.5; P<.0001). There was recovery of in vitro fertilization outcomes following washout in the short-term treatment cohort, with incomplete reversibility in the long-term cohort. Testosterone did not negatively affect maturity, fertilization, or blastulation rates.
In a mouse model of gender-affirming hormone treatment, testosterone negatively affected oocyte yield without affecting oocyte quality. Our findings suggest that testosterone reversibility is duration-dependent. These results demonstrate the feasibility of in vitro fertilization without testosterone discontinuation while supporting a washout period for optimization of mature oocyte yield.
性别肯定型睾丸激素对生育能力的影响知之甚少,卵巢组织病理学研究结果不一,有些对生殖能力有不利影响,而且其可逆性不确定。辅助生殖结局数据仅限于缺乏告知临床实践指南和限制跨性别和非二进制个体生育力保存咨询能力的小型病例系列。
本研究旨在确定当前睾丸激素和睾丸激素洗脱对性别肯定型激素治疗的小鼠模型中体外受精结局的影响。我们假设当前或以前的睾丸激素治疗不会影响体外受精结局。
C57BL/6N 雌性小鼠(n=120)被分为 4 个治疗组:(1)当前对照,(2)当前睾丸激素,(3)对照洗脱,和(4)睾丸激素洗脱。睾丸激素植入物在原位保留 6 或 12 周,分别代表短期和长期治疗臂。当前治疗组在植入物在位时进行卵巢刺激,洗脱治疗组在 2 周后取出并进行卵巢刺激。收集卵母细胞,体外受精和培养,其中一个臂继续到囊胚阶段,另一个臂进行卵裂期胚胎移植。使用 GraphPad Prism,版本 9.0 和 R 统计软件,版本 4.1.2 进行统计分析,统计显著性定义为 P<.05。
当前长期睾丸激素治疗会损害体外受精结局,导致可回收的成熟卵母细胞数量减少(13.7±5.1 [标准差] 与 28.6±7.8 [标准差];P<.0001),导致卵裂期胚胎数量减少(12.1±5.1 与 26.5±8.2;P<.0001)和囊胚数量减少(10.0±3.2 与 25.0±6.5;P<.0001)。在短期治疗队列中,洗脱后体外受精结局恢复,但在长期队列中恢复不完全。睾丸激素不会降低卵母细胞成熟、受精或囊胚形成率。
在性别肯定型激素治疗的小鼠模型中,睾丸激素会降低卵母细胞产量,而不会影响卵母细胞质量。我们的研究结果表明,睾丸激素的可逆性与持续时间有关。这些结果证明了在不停止睾丸激素的情况下进行体外受精的可行性,同时支持洗脱期以优化成熟卵母细胞产量。